Zevra Therapeutics (ZVRA) Common Equity (2014 - 2026)

Zevra Therapeutics has reported Common Equity for 13 years, with the latest figure at $205.8 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 401.68% year-over-year to $205.8 million; the trailing twelve-month figure through Mar 2026 stood at $205.8 million (up 401.68% YoY), and the FY2025 full-year result was $154.7 million, up 289.9% from the prior year.
• Common Equity for Q1 2026 stood at $205.8 million, up from $154.7 million in the prior quarter.
• The five-year high for Common Equity was $435.1 million in Q3 2022, with the low at -$338.4 million in Q2 2022.
• Historically, Common Equity has averaged $78.5 million across 5 years, with a median of $61.7 million in 2023.
• Annual changes were most pronounced in 2022 — Common Equity slumped 359.02% — and 2026, when it soared 401.68%.
• Zevra Therapeutics' Common Equity stood at $75.1 million in 2022, then declined by 17.65% to $61.9 million in 2023, then slumped by 35.88% to $39.7 million in 2024, then surged by 289.9% to $154.7 million in 2025, then soared by 33.07% to $205.8 million in 2026.
• The last three Common Equity figures came in at $205.8 million (Q1 2026), $154.7 million (Q4 2025), and $133.2 million (Q3 2025), per Business Quant data.